Swedish Orphan Valuation
| B6E Stock | EUR 26.86 0.42 1.59% |
At this time, the company appears to be overvalued. Swedish Orphan Biovitrum has a current Real Value of €22.8 per share. The regular price of the company is €26.86. Our model measures the value of Swedish Orphan Biovitrum from inspecting the company fundamentals such as Current Valuation of 6.67 B, return on equity of 0.11, and Shares Owned By Insiders of 4.00 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Swedish Orphan's price fluctuation is not too volatile at this time. Calculation of the real value of Swedish Orphan Biovitrum is based on 3 months time horizon. Increasing Swedish Orphan's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Swedish stock is determined by what a typical buyer is willing to pay for full or partial control of Swedish Orphan Biovitrum. Since Swedish Orphan is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Swedish Stock. However, Swedish Orphan's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 26.86 | Real 22.8 | Hype 26.86 |
The real value of Swedish Stock, also known as its intrinsic value, is the underlying worth of Swedish Orphan Biovitrum Company, which is reflected in its stock price. It is based on Swedish Orphan's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Swedish Orphan's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Swedish Orphan Biovitrum helps investors to forecast how Swedish stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Swedish Orphan more accurately as focusing exclusively on Swedish Orphan's fundamentals will not take into account other important factors: Swedish Orphan Total Value Analysis
Swedish Orphan Biovitrum is currently estimated to have takeover price of 6.67 B with market capitalization of 6.36 B, debt of 8.78 B, and cash on hands of 280.15 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Swedish Orphan fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.67 B | 6.36 B | 8.78 B | 280.15 M |
Swedish Orphan Investor Information
About 70.0% of the company shares are held by institutions such as insurance companies. The book value of Swedish Orphan was currently reported as 3.55. The company had not issued any dividends in recent years. Based on the analysis of Swedish Orphan's profitability, liquidity, and operating efficiency, Swedish Orphan Biovitrum is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Swedish Orphan Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Swedish Orphan has an asset utilization ratio of 31.91 percent. This implies that the Company is making €0.32 for each dollar of assets. An increasing asset utilization means that Swedish Orphan Biovitrum is more efficient with each dollar of assets it utilizes for everyday operations.Swedish Orphan Ownership Allocation
Swedish Orphan Biovitrum shows a total of 295.99 Million outstanding shares. Over half of Swedish Orphan's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Swedish Orphan Biovitrum. Please watch out for any change in the institutional holdings of Swedish Orphan as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Swedish Orphan Profitability Analysis
The company reported the revenue of 15.53 B. Net Income was 2.68 B with profit before overhead, payroll, taxes, and interest of 14.38 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Swedish Orphan's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Swedish Orphan and how it compares across the competition.
About Swedish Orphan Valuation
The stock valuation mechanism determines Swedish Orphan's current worth on a weekly basis. Our valuation model uses a comparative analysis of Swedish Orphan. We calculate exposure to Swedish Orphan's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Swedish Orphan's related companies.Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. SWEDISH ORPHAN is traded on Frankfurt Stock Exchange in Germany.
8 Steps to conduct Swedish Orphan's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Swedish Orphan's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Swedish Orphan's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Swedish Orphan's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Swedish Orphan's revenue streams: Identify Swedish Orphan's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Swedish Orphan's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Swedish Orphan's growth potential: Evaluate Swedish Orphan's management, business model, and growth potential.
- Determine Swedish Orphan's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Swedish Orphan's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Swedish Stock analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |